Seaport Therapeutics, Inc. Common Stock (SPTX) Stock
Key stats
- Market cap
- $1.14B
- Price / Earnings ratio
- -15.7x
- EPS (TTM)
- -$31.54
- Volume
- Loading
- 52-week high
- $28.38
- 52-week low
- $14.85
Source: third-party data provider, as of November 13, 2026
Compare with SPTX
Recent news

Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
SPTX

Seaport Therapeutics to Present at Stifel 2026 Healthcare Conference
Seaport Therapeutics to Present at Stifel 2026 Healthcare Conference
SPTX

PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
SPTX

Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
SPTX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 55.29
- MACD 12/26/9
- 0.46
- EMA 9 of MACD
- 0.22
- MACD histogram
- 0.24
- SMA 50
- $20.55
- Price above SMA 50
- EMA 50
- $20.50
- Price above EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
SPTX

Seaport Therapeutics to Present at Stifel 2026 Healthcare Conference
Seaport Therapeutics to Present at Stifel 2026 Healthcare Conference
SPTX

PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
SPTX

Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
SPTX

Seaport Therapeutics to Participate in September Investor Conferences
Seaport Therapeutics to Participate in September Investor Conferences
SPTX

PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
SPTX

Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
SPTX

Seaport Therapeutics to Present at Citi's 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference
Seaport Therapeutics to Present at Citi's 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference
SPTX

Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO
SPTX

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
SPTX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Seaport Therapeutics, Inc. Common Stock
Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for depression, anxiety, and other neuropsychiatric disorders. The company’s approach centers on targeting clinically validated mechanisms with established efficacy and safety profiles, while addressing historical limitations such as high first-pass metabolism, low bioavailability, and adverse side effects.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Daphne Zohar | Founder, CEO, President & Director | 1971 |
| Dr. Steven M. Paul M.D. | Founder & Non-Employee Chair of the Board | 1951 |
| Ms. Lauren A. White M.B.A. | Chief Financial Officer | 1979 |
| Dr. Michael Cunyuan Chen Ph.D. | Co-Founder & Chief Scientific Officer | 1984 |
| Dr. Antony Loebel M.D. | Chief Medical Officer & President of Clinical Development | 1961 |
| Ms. Lana Gladstein J.D. | General Counsel | 1976 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 55.29
- MACD 12/26/9
- 0.46
- EMA 9 of MACD
- 0.22
- MACD histogram
- 0.24
- SMA 50
- $20.55
- Price above SMA 50
- EMA 50
- $20.50
- Price above EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $28.00
- Average
- $39.40
- High
- $50.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -8.3 | +26.8 | -4.6 | +14.7 | -14.6 | +3.4 | +6.5 |



